Automation in Biopharma: Transforming Cell Line and Process Development

The biopharma industry is undergoing rapid growth and rising complexity, particularly in cell line development (CLD) and upstream process (USP) optimization. Demand for high-yield biologics such as monoclonal antibodies, bispecifics, Fc-fusion proteins, enzymes, vaccines, and biosimilars continues to accelerate. At the same time, advances in cell and gene therapy (CGT) and mRNA technologies are generating unprecedented volumes of experimental data. As a result, manual, spreadsheet-driven workflows and paper-based records no longer scale.

Sartorius, a global leader in bioprocess technologies and CDMO services, clearly articulated the impact of these limitations. As the organization grows, data processing becomes a major bottleneck. With work tracked across Excel files, Word documents, and even physical records, the approach no longer scaled when throughput increased from a handful of cell lines to around 80 per year. To overcome these challenges, Sartorius deployed Genedata Bioprocess, part of the Genedata Biopharma platform, as its enterprise digital backbone, enabling a threefold increase in CLD and USP throughput without adding headcount, as reported by Hugo de Wit, Head of Business Area Cell Culture Technologies at Sartorius.​​

Key Challenges in Biopharma Cell Line and Process Development

Biopharma organizations often struggle with limited integration between laboratory instruments, databases, and analytics systems. This lack of connectivity forces teams to rely on manual data recording, processing, and reconciliation — approaches that cannot support the scale and speed required for modern CLD. As teams manage hundreds of clones across transfection, selection, and scale-up stages, maintaining accuracy and efficiency becomes increasingly difficult¹.

Sartorius encountered these same obstacles when its CLD output expanded from four to ten cell lines per year to more than eighty. Manual processes quickly reached their operational limits, exposing several bottlenecks:

• Fragmented Data Handling: Teams spent excessive time consolidating outputs from Ambr^® 15 bioreactors, Octet analyzers, FACS sorters, and liquid handlers for both in-project and cross-project analyses.
• Data Silos: Limited integration restricted real-time decision-making and slowed progress toward paperless operations.
• Scaling Complexity: These issues intensified as Sartorius expanded its proprietary CHO DG44 platform with optimized, animal-component-free media systems.​​

To overcome these limitations, Sartorius needed a centralized digital solution capable of managing complex, high-throughput CLD workflows.

Solving the Biopharma Automation Challenge: Integrated Digital Solutions for End-to-End Development

A centralized, automated digital backbone is essential for connecting every stage of development into a seamless, traceable workflow —  from vector design and nucleofection through mini-pool generation, FACS-based clone sorting, fed-batch evaluation in Ambr^® 15/250 systems, and scale-up to 2,000-liter bioreactors. To support this complexity, Sartorius selected a commercial off-the-shelf enterprise workflow system that provides barcoded sample tracking, coordination of laboratory automation, and native integration with Sartorius instruments, including robotic automation stations, plate hotels, cell imagers, and liquid dispensers.

Genedata Bioprocess delivers a comprehensive, out-of-the-box solution purpose-built for biopharma. It automates CHO transfections², plasmid optimization, media development, and USP design, while ensuring end-to-end connectivity with analytics tools such as Vicell^®, CellaVista, and HPLC systems. The platform reduces manual work and strengthens data integrity by:

• Automating data capture and transfer to streamline laboratory automation
• Improving data integrity through error-proof protocols
• Enabling real-time monitoring of key performance metrics such as titer, monoclonality³, viable cell density (VCD), and metabolites
• Supporting regulatory compliance with comprehensive audit trails and rapid deployment timelines​​

Core Capabilities of Modern Biopharma Automation Systems

Genedata Bioprocess streamlines biopharma R&D by converting instrument outputs into clear, actionable insights. Its architecture enables global teams to standardize processes, reduce variability, and accelerate decision-making across the organization.​​

Advantages of End-to-End Workflow Automation

Sartorius eliminated manual handoffs by unifying previously disconnected steps into a single, barcoded workflow⁴. This integrated pipeline spans vector construction, MTX-free mini-pool generation, titer-based clone selection and batch productivity assessment. By automating the full CLD process, Sartorius consistently supports a 14-week DNA-to-research cell bank (RCB) timeline while overcoming the scalability limits of paper-based records. 

Through end-to-end laboratory automation, Sartorius’  liquid-handling robots and incubators now process hundreds of clones in parallel, delivering high throughput without sacrificing precision. Configurable workflow templates preserve experimental flexibility while enforcing standardization to minimize variability and rework. These capabilities also coordinate the interplay between the central automation station and downstream bioreactors⁵, enabling continuous operation with minimal human oversight and freeing scientists to focus on higher-value activities.​​

Real-Time Monitoring and Decision Support

Real-time dashboards aggregate time-course data from 48-parallel Ambr^® 15 (15 mL) or Ambr^® 250 (250 mL) fermentations, along with offline metrics from Univessel^® 5 L and Biostat^® 50 L systems. This visibility enables teams to track key growth attributes — such as pH, pO₂, qP, lactate, and confluence — across clone candidates. Built-in statistics and interactive visualizations support rapid identification of high performers, process deviations, and media optimization opportunities.

This centralized insight aligns with quality-by-design (QbD) principles and strengthens decision-making. For Sartorius, these capabilities transformed resource allocation by allowing teams to benchmark clones against parameters such as batch titer and scalability to manufacturing, thereby shortening paths to Biologics License Application (BLA) and Investigational New Drug (IND) submissions.​​ 

Rapid Deployment with Commercial Digital Solutions 

Off-the-shelf digital solutions accelerate value realization by providing pre-validated workflows, instrument connectors, and embedded domain expertise — avoiding the long timelines associated with custom-built software. At Sartorius, Genedata Bioprocess enabled onboarding within weeks through scientific consulting, cross-team training, and seamless integration with existing robotics and analytics tools⁶, all without heavy customization.

This approach scaled effectively to Sartorius’ new 6,000 m² R&D center while supporting their proprietary DG44 processes. The platform’s flexible architecture also demonstrated the adaptability required for diverse CGT modalities, including CAR T, AAV, and NK cells.

The Impact of Automation on Biopharma: Tripling Productivity While Enhancing Quality

Implementing Genedata Bioprocess significantly improved accuracy at Sartorius by automating documentation and data flows. This shift reduced manual effort, accelerated the move toward paperless operations, and mitigated human-error risks in high-throughput CLD processes. Scalability improved through streamlined global data access, better team communication, and continuous screening capabilities.

Digitalization also strengthened technology transfer processes and operational resilience across distributed sites. Beyond immediate efficiency gains, the platform positioned Sartorius for sustained growth, supporting future expansion into CGT and mRNA programs by embedding automation into core workflows.​​

Automation delivered measurable business value through rigorous benchmarking and quantifiable ROI, transforming Sartorius from manual, capacity-restricted operations into a scalable, high-velocity model.​​

Tripled Productivity and Throughput

Sartorius tripled its annual output of high-yield CHO DG44 lines without adding headcount. Automated barcoded tracking and integrated workflows supported uninterrupted progression from nucleofection and FACS sorting through fed-batch evaluation in Ambr^® systems. This increased capacity enabled Sartorius to keep pace with rising biopharma demand.
 

Accelerated Project Timelines

Automation shortened the DNA-to-RCB timeline from 14 weeks by integrating data across vector design, mini-pool generation, and bioreactor scale-up in Ambr^® 15, Ambr^® 250, and Univessel^® 5 L systems. Real-time outlier detection, statistical analysis of titers and metabolites, and decision-support dashboards reduced delays and accelerated readiness for  BLA/IND submissions — supporting rapid progression to 2,000-liter manufacturing.​​

Significant Cost Reductions

More precise clone selection and fewer experimental repeats delivered cost savings per project. Automated liquid handling, media preparation, and analytics integration optimized resource utilization across robotics, incubators, and assay systems. These efficiencies reduced overall R&D spending while maintaining high-titer production across mAbs, bispecifics, and biosimilars.

Enhanced Data Integrity and Compliance

Automated data capture from Octet^®, Vi-cell^®, CellaVista, and HPLC systems produced complete, error-free records with robust audit trails. Eliminating manual entry reduced documentation access time by more than 30% and strengthened regulatory readiness, while improving QbD insights into parameters such as growth profiles, pH, VCD, and qP metrics.​​

Global Team Collaboration and Scalability

Centralized, real-time tracking gave distributed teams and customers unified access, improving cross-site collaboration and technology transfer. These capabilities supported Sartorius’ 6,000 m² R&D expansion and the integration of advanced CGT workflows, including CAR T and AAV. Standardized workflows and proactive resource planning enabled rapid scaling without operational interruptions.

Sartorius successfully transformed its biopharma R&D operations by adopting a commercial off-the-shelf solution using Genedata Bioprocess. This integrated approach increased throughput, strengthened quality and compliance, and delivered immediate ROI — while establishing a scalable digital model for future biologics and CGT development.

Learn how Sartorius tripled cell line and process development throughput with an end-to-end digital backbone powered by Genedata Bioprocess^®.

References

1. Niklas, J.; Retey, J.; Fehrmann, S.; Macko, L.; Hartsch, T.; Adamczyk, B. A New Integrated Knowledge Management & Data Analysis Platform for Cell Line Development & Cell Culture R&D. BMC Proc.2015, 9 (S9), P63, 1753-6561-9-S9-P63. https://doi.org/10.1186/1753-6561-9-S9-P63.
2. Ganapathy, K.; Lam, C.; Tsukuda, J.; Sargon, A.; Nava, A.; Harms, P.; Shen, A.; Barnard, G.; Misaghi, S. SPEED‐MODE Cell Line Development ( CLD ): Reducing Chinese Hamster Ovary ( CHO ) CLD Timelines via Earlier Suspension Adaptation and Maximizing Time Spent in the Exponential Growth Phase. Biotechnol. Prog.2024, 40 (5), e3479. https://doi.org/10.1002/btpr.3479.
3. Layton, D.; Laverty, C.; Nice, E. C. Design and Operation of an Automated High-Throughput Monoclonal Antibody Facility. Biophys. Rev.2013, 5 (1), 47–55. https://doi.org/10.1007/s12551-012-0095-6.
4. Bauer, N.; Oberist, C.; Poth, M.; Stingele, J.; Popp, O.; Ausländer, S. Genomic Barcoding for Clonal Diversity Monitoring and Control in Cell-Based Complex Antibody Production. Sci. Rep.2024, 14 (1), 14587. https://doi.org/10.1038/s41598-024-65323-7.
5. Mitra, S.; Murthy, G. S. Bioreactor Control Systems in the Biopharmaceutical Industry: A Critical Perspective. Syst. Microbiol. Biomanufacturing2022, 2 (1), 91–112. https://doi.org/10.1007/s43393-021-00048-6.
6. Banner, M.; Alosert, H.; Spencer, C.; Cheeks, M.; Farid, S. S.; Thomas, M.; Goldrick, S. A Decade in Review: Use of Data Analytics within the Biopharmaceutical Sector. Curr. Opin. Chem. Eng.2021, 34, 100758. https://doi.org/10.1016/j.coche.2021.100758.